Efficacy Outcomes: Progression-Free Survival, Response Rates, and Duration of Response in MARIPOSA-2

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Alectinib exhibited a CNS DFS improvement, with a 63% reduction in the risk of this event, and 4-year CNS DFS rate was 90.4% vs 76.1% with chemotherapy.

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Data from the KEYNOTE-671 trial support the use of pembrolizumab among patients with non–small cell lung cancer in the perioperative setting.

Data from the phase 3 HARMONi-6 study may support ivonescimab plus chemotherapy as a new standard of care in advanced squamous non–small cell lung cancer.